MLR-1023 was discovered and developed internally using Melior’s indications discovery platform, theraTRACE.
Andrew Reaume, president and CEO of Melior, said: “We are delighted to have been given the go-ahead by the FDA to advance MLR-1023 into clinical development. This investigational new drug (IND) application represents a major milestone for Melior Discovery, and underscores the productivity of our theraTRACE indications discovery engine. In addition to MLR-1023, we have a number of other programs also progressing towards the clinic.”